Person who experienced the adverse event (patient)
| Event ID | CASEID | CASEVERSION | I F COD | EVENT DT | MFR DT | INIT FDA DT | FDA DT | REPT COD | AUTH NUM | MFR NUM | MFR SNDR | LIT REF | AGE | AGE COD | AGE GRP | GNDR COD | E SUB | WT | WT COD | REPT DT | TO MFR | OCCP COD | REPORTER COUNTRY | OCCR COUNTRY |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 125557461 | 12555746 | 1 | I | 20160705 | 20160714 | 20160714 | EXP | US-GLENMARK PHARMACEUTICALS INC, USA.-2016GMK023583 | GLENMARK | GOLOMB B A, KOSLIK H J, REDD A J. FLUOROQUINOLONE-INDUCED SERIOUS, PERSISTENT, MULTISYMPTOM ADVERSE EFFECTS.. BMJ CASE REPORTS. 2015 | 55.00 | YR | F | Y | 0.00000 | 20160714 | MD | US | US |
Drug(s) used by person
| Event ID | CASEID | DRUG SEQ | ROLE COD | DRUGNAME | PROD AI | VAL VBM | ROUTE | DOSE VBM | CUM DOSE CHR | CUM DOSE UNIT | DECHAL | RECHAL | LOT NUM | EXP DT | NDA NUM | DOSE AMT | DOSE UNIT | DOSE FORM | DOSE FREQ |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 125557461 | 12555746 | 1 | PS | LEVOFLOXACIN. | LEVOFLOXACIN | 1 | Unknown | 500 MG, QD | U | 200250 | 500 | MG | |||||||
| 125557461 | 12555746 | 2 | SS | LEVOFLOXACIN. | LEVOFLOXACIN | 1 | 750 MG, UNK | U | 200250 | 750 | MG | ||||||||
| 125557461 | 12555746 | 3 | C | ALENDRONIC ACID | ALENDRONIC ACID | 1 | Unknown | UNK | 0 |
Indications of drugs used
| Event ID | CASEID | INDI DRUG SEQ | INDI PT |
|---|---|---|---|
| 125557461 | 12555746 | 1 | Sinusitis |
| 125557461 | 12555746 | 2 | Urinary tract infection |
| 125557461 | 12555746 | 3 | Osteoporosis |
Outcome of event
| Event ID | CASEID | OUTC COD |
|---|---|---|
| 125557461 | 12555746 | OT |
| 125557461 | 12555746 | DS |
Reactions reported
| Event ID | CASEID | DRUG REC ACT | PT |
|---|---|---|---|
| 125557461 | 12555746 | Affective disorder | |
| 125557461 | 12555746 | Alopecia | |
| 125557461 | 12555746 | Amnesia | |
| 125557461 | 12555746 | Anxiety | |
| 125557461 | 12555746 | Arthralgia | |
| 125557461 | 12555746 | Cognitive disorder | |
| 125557461 | 12555746 | Confusional state | |
| 125557461 | 12555746 | Eye disorder | |
| 125557461 | 12555746 | Fatigue | |
| 125557461 | 12555746 | Headache | |
| 125557461 | 12555746 | Mental disorder | |
| 125557461 | 12555746 | Muscular weakness | |
| 125557461 | 12555746 | Myalgia | |
| 125557461 | 12555746 | Nervous system disorder | |
| 125557461 | 12555746 | Neuropathy peripheral | |
| 125557461 | 12555746 | Pain | |
| 125557461 | 12555746 | Respiratory muscle weakness | |
| 125557461 | 12555746 | Sensory disturbance | |
| 125557461 | 12555746 | Somnolence | |
| 125557461 | 12555746 | Tendon disorder | |
| 125557461 | 12555746 | Tinnitus | |
| 125557461 | 12555746 | Toxicity to various agents |
Reporting Sources (this data is often not reported and may therefore be missing here)
| no results found |
Therapies reported
| no results found |